On October 7, 2021 Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, reported the following statement concerning the inadvertent issuance of an abstract by the AACR (Free AACR Whitepaper)-NCI-EORTC Virtual AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) ("ANE Conference") concerning an upcoming oral presentation of initial monotherapy clinical data from its ongoing Phase 1/2 clinical trial of RP-3500 (Press release, Repare Therapeutics, OCT 7, 2021, View Source [SID1234590957]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Repare was alerted to the ANE Conference’s inadvertent early issuance of an abstract highlighting the upcoming oral presentation of initial monotherapy clinical data from the Company’s ongoing Phase 1/2 clinical trial of RP-3500. The Abstract highlights results taken from a very early cutoff date for the ongoing study, currently in its Phase 1 portion. The oral presentation, which will be delivered by Dr. Timothy Yap, MBBS, Ph.D., FRCP, Medical Director, Institute for Applied Cancer Science, Associate Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, Texas, and which is expect to take place on Friday, October 8, 2021 at 3:15 p.m. ET, will include both significantly more patient data as well as a later cut off date and consequent longer follow up."

Company Virtual Investor Webcast Event Details

The Company has also announced that it will host a virtual investor webcast on Friday, October 8, 2021 at 5:00 p.m. ET to further discuss the data, where Repare’s executive management team will be joined by Dr. Yap. This Company’s presentation will include additional updates from past the cutoff date for the ANE Conference presentation. The Company looks forward to both presentations and to sharing results from these substantial updates.

To join the Company’s live video webcast, go to the Investor section of the Company’s website at View Source The Webcast will begin at 5:00 p.m. ET on Friday, October 8, 2021. A webcast replay will also be archived for at least 30 days.

About Repare Therapeutics’ SNIPRx Platform

Repare’s SNIPRx platform is a genome-wide CRISPR-based screening approach that utilizes proprietary isogenic cell lines to identify novel and known synthetic lethal gene pairs and the corresponding patients who are most likely to benefit from the Company’s therapies based on the genetic profile of their tumors. Repare’s platform enables the development of precision therapeutics in patients whose tumors contain one or more genomic alterations identified by SNIPRx screening, in order to selectively target those tumors in patients most likely to achieve clinical benefit from resulting product candidates.